Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Simvastatin ameliorates experimental autoimmune encephalomyelitis by inhibiting Th1/Th17 response and cellular infiltration (2015)

  • Authors:
  • USP affiliated authors: FERRARI, MERARI DE FATIMA RAMIRES - IB ; HIYANE, MEIRE IOSHIE - ICB ; CÂMARA, NIELS OLSEN SARAIVA - ICB ; PERON, JEAN PIERRE SCHATZMANN - ICB
  • USP Schools: IB; ICB; ICB; ICB
  • DOI: 10.1007/s10787-015-0252-1
  • Subjects: DOENÇAS AUTOIMUNES; SISTEMA NERVOSO CENTRAL; ESCLEROSE MÚLTIPLA; INFLAMAÇÃO; ENCEFALOMIELITE ANIMAL; PROLIFERAÇÃO CELULAR; FÁRMACOS
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1007/s10787-015-0252-1 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Versões disponíveis em Acesso Aberto do: 10.1007/s10787-015-0252-1 (Fonte: Unpaywall API)

    Título do periódico: Inflammopharmacology

    ISSN: 0925-4692,1568-5608



      Não possui versão em Acesso aberto
    Informações sobre o Citescore
  • Título: Inflammopharmacology

    ISSN: 0925-4692

    Citescore - 2017: 3.05

    SJR - 2017: 0.925

    SNIP - 2017: 1.144


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    ICB12100123608PC ICB BMI SEP 2015
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      OLIVEIRA, Daniel May de; OLIVEIRA, Enedina Maria Lobato de; FERRARI, Merari de Fatima Ramires; et al. Simvastatin ameliorates experimental autoimmune encephalomyelitis by inhibiting Th1/Th17 response and cellular infiltration. Inflammopharmacology, Basel, v. 23, n. 6, p. 343-354, 2015. Disponível em: < http://dx.doi.org/10.1007/s10787-015-0252-1 > DOI: 10.1007/s10787-015-0252-1.
    • APA

      Oliveira, D. M. de, Oliveira, E. M. L. de, Ferrari, M. de F. R., Semedo, P., Hiyane, M. I., Cenedeze, M. A., et al. (2015). Simvastatin ameliorates experimental autoimmune encephalomyelitis by inhibiting Th1/Th17 response and cellular infiltration. Inflammopharmacology, 23( 6), 343-354. doi:10.1007/s10787-015-0252-1
    • NLM

      Oliveira DM de, Oliveira EML de, Ferrari M de FR, Semedo P, Hiyane MI, Cenedeze MA, Pacheco-Silva A, Câmara NOS, Peron JPS. Simvastatin ameliorates experimental autoimmune encephalomyelitis by inhibiting Th1/Th17 response and cellular infiltration [Internet]. Inflammopharmacology. 2015 ; 23( 6): 343-354.Available from: http://dx.doi.org/10.1007/s10787-015-0252-1
    • Vancouver

      Oliveira DM de, Oliveira EML de, Ferrari M de FR, Semedo P, Hiyane MI, Cenedeze MA, Pacheco-Silva A, Câmara NOS, Peron JPS. Simvastatin ameliorates experimental autoimmune encephalomyelitis by inhibiting Th1/Th17 response and cellular infiltration [Internet]. Inflammopharmacology. 2015 ; 23( 6): 343-354.Available from: http://dx.doi.org/10.1007/s10787-015-0252-1

    Referências citadas na obra
    Ando DG, Clayton J, Kono D, Urban JL, Sercarz EE (1989) Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol 124:132–143
    Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, de Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, Polman CH, de Waal Malefyt R, Steinman L, Raman C (2010) T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 16:406–412
    Bagaeva LV, Williams LP, Segal BM (2003) IL-12 dependent/IFN gamma independent expression of CCR5 by myelin-reactive T cells correlates with encephalitogenicity. J Neuroimmunol 137:109–116
    Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, Bernini F (1998) HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18:1671–1678
    Bettelli E, Sullivan B, Szabo SJ, Sobel RA, Glimcher LH, Kuchroo VK (2004) Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J Exp Med 200:79–87
    Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235–238
    Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT (2008) Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 71:1390–1395
    Brocke S, Gijbels K, Allegretta M, Ferber I, Piercy C, Blankenstein T, Martin R, Utz U, Karin N, Mitchell D, Veromaa T, Waisman A, Gaur A, Conlon P, Ling N, Fairchild PJ, Wraith DC, O’Garra A, Fathman CG, Steinman L (1996) Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 379:343–346
    Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez F, Diaz C, Hernandez G, Egido J (1998) HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 32:2057–2064
    Chataway J, Schuerer N, Alsanousi A, Chan D, Macmanus D, Hunter K, Anderson V, Bangham CR, Clegg S, Nielsen C, Fox NC, Wilkie D, Nicholas JM, Calder VL, Greenwood J, Frost C, Nicholas R (2014) Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 383:2213–2221
    Compston A, Coles A (2002) Multiple sclerosis. Lancet 359:1221–1231
    Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD (2003) Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421:744–748
    Eller P, Eller K, Wolf AM, Reinstadler SJ, Tagwerker A, Patsch JR, Mayer G, Rosenkranz AR (2010) Atorvastatin attenuates murine anti-glomerular basement membrane glomerulonephritis. Kidney Int 77:428–435
    Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, Steinman L, Dalton D, Fathman CG (1996) Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 156:5–7
    Frohman EM, Racke MK, Raine CS (2006) Multiple sclerosis—the plaque and its pathogenesis. N Engl J Med 354:942–955
    Ganne F, Vasse M, Beaudeux JL, Peynet J, Francois A, Mishal Z, Chartier A, Tobelem G, Vannier JP, Soria J, Soria C (2000) Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes–a possible protective mechanism against atherothrombosis. Thromb Haemost 84:680–688
    Glabinski AR, Tani M, Tuohy VK, Tuthill RJ, Ransohoff RM (1995) Central nervous system chemokine mRNA accumulation follows initial leukocyte entry at the onset of acute murine experimental autoimmune encephalomyelitis. Brain Behav Immun 9:315–330
    Glabinski AR, Tani M, Strieter RM, Tuohy VK, Ransohoff RM (1997) Synchronous synthesis of alpha- and beta-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am J Pathol 150:617–630
    Godiska R, Chantry D, Dietsch GN, Gray PW (1995) Chemokine expression in murine experimental allergic encephalomyelitis. J Neuroimmunol 58:167–176
    Hu W, Lucchinetti CF (2009) The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol 31:439–453
    Imamura M, Okunishi K, Ohtsu H, Nakagome K, Harada H, Tanaka R, Yamamoto K, Dohi M (2009) Pravastatin attenuates allergic airway inflammation by suppressing antigen sensitisation, interleukin 17 production and antigen presentation in the lung. Thorax 64:44–49
    Ishizu T, Osoegawa M, Mei FJ, Kikuchi H, Tanaka M, Takakura Y, Minohara M, Murai H, Mihara F, Taniwaki T, Kira J (2005) Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 128:988–1002
    Kamm CP, El-Koussy M, Humpert S, Findling O, von Bredow F, Burren Y, Schwegler G, Schott D, Donati F, Muller M, Goebels N, Muller F, Slotboom J, Tettenborn B, Kappos L, Naegelin Y, Mattle HP (2012) Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial. J Neurol 259:2401–2413
    Kamm CP, El-Koussy M, Humpert S, Findling O, Burren Y, Schwegler G, Donati F, Muller M, Muller F, Slotboom J, Kappos L, Naegelin Y, Mattle HP (2014) Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial. PLoS ONE 9:e86663
    Kim SY, Guijarro C, O’Donnell MP, Kasiske BL, Kim Y, Keane WF (1995) Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin. Kidney Int 48:363–371
    Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA et al (1995) Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333:621–627
    Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM (2008) IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med 205:1535–1541
    Kuchroo VK, Anderson AC, Waldner H, Munder M, Bettelli E, Nicholson LB (2002) T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu Rev Immunol 20:101–123
    Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233–240
    Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V (2010) Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler 16:450–454
    Lavi E, Constantinescu CS (2005) Experimental models of multiple sclerosis. Springer, New York
    Li Z, Chen L, Niu X, Liu J, Ping M, Li R, Xie X, Guo L (2012) Immunomodulatory synergy by combining atorvastatin and rapamycin in the treatment of experimental autoimmune encephalomyelitis (EAE). J Neuroimmunol 250:9–17
    Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L (2002) Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8:500–508
    Luccarini I, Ballerini C, Biagioli T, Biamonte F, Bellucci A, Rosi MC, Grossi C, Massacesi L, Casamenti F (2008) Combined treatment with atorvastatin and minocycline suppresses severity of EAE. Exp Neurol 211:214–226
    Matusevicius D, Kivisakk P, Navikas VV, Tian W, Soderstrom M, Fredrikson S, Link H (1998) Influence of IFN-beta1b (Betaferon) on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM-1 in multiple sclerosis. Eur J Neurol 5:265–275
    Murphy DM, Forrest IA, Corris PA, Johnson GE, Small T, Jones D, Fisher AJ, Egan JJ, Cawston TE, Ward C, Lordan JL (2008) Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients. Am J Physiol Lung Cell Mol Physiol 294:L592–L599
    Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier BC, Niederwieser G, Hartung HP, Archelos JJ (2002) Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59:990–997
    Neuhaus O, Stuve O, Archelos JJ, Hartung HP (2005) Putative mechanisms of action of statins in multiple sclerosis—comparison to interferon-beta and glatiramer acetate. J Neurol Sci 233:173–177
    Pahan K, Sheikh FG, Namboodiri AM, Singh I (1997) Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 100:2671–2679
    Paintlia AS, Paintlia MK, Singh AK, Stanislaus R, Gilg AG, Barbosa E, Singh I (2004) Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin. J Neurosci Res 77:63–81
    Paintlia AS, Paintlia MK, Hollis BW, Singh AK, Singh I (2012) Interference with RhoA-ROCK signaling mechanism in autoreactive CD4+ T cells enhances the bioavailability of 1,25-dihydroxyvitamin D3 in experimental autoimmune encephalomyelitis. Am J Pathol 181:993–1006
    Panitch HS, Hirsch RL, Haley AS, Johnson KP (1987) Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1:893–895
    Peron JPS, Oliveira D, Brandão WN, Fickinger A, Ligeiro De Oliveira AP, Rizzo LV, Câmara NOS (2012) Central nervous system resident cells in neuroinflammation: a brave new world. In: Chan J (ed) Autoimmune diseases, contributing factors, specific cases of autoimmune diseases, and stem cell and other therapies. InTech, Rijeka
    Rallidis LS, Hamodraka ES, Fountoulaki K, Moustogiannis G, Zolindaki MG, Kremastinos DT (2008) Simvastatin exerts its anti-inflammatory effect in hypercholesterolaemic patients by decreasing the serum levels of monocyte chemoattractant protein-1. Int J Cardiol 124:271–272
    Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, Uccelli A, Lanzavecchia A, Engelhardt B, Sallusto F (2009) C–C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 10:514–523
    Saito A, Saito N, Mol W, Furukawa H, Tsutsumida A, Oyama A, Sekido M, Sasaki S, Yamamoto Y (2008) Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res 18:85–94
    Sierra S, Ramos MC, Molina P, Esteo C, Vazquez JA, Burgos JS (2011) Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood–brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis 23:307–318
    Sorensen PS, Lycke J, Eralinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmestrom C, Stenager E, Sellebjerg F, Sondergaard HB (2011) Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol 10:691–701
    Stuve O, Youssef S, Weber MS, Nessler S, von Budingen HC, Hemmer B, Prod’Homme T, Sobel RA, Steinman L, Zamvil SS (2006) Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 116:1037–1044
    Tani M, Glabinski AR, Tuohy VK, Stoler MH, Estes ML, Ransohoff RM (1996) In situ hybridization analysis of glial fibrillary acidic protein mRNA reveals evidence of biphasic astrocyte activation during acute experimental autoimmune encephalomyelitis. Am J Pathol 148:889–896
    Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M (2010) Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Mult Scler 16:848–854
    Tsakiri A, Kallenbach K, Fuglo D, Wanscher B, Larsson H, Frederiksen J (2012) Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. Mult Scler 18:72–81
    Vieira JM Jr, Mantovani E, Rodrigues LT, Delle H, Noronha IL, Fujihara CK, Zatz R (2005) Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrol Dial Transpl 20:1582–1591
    Voskuhl RR, Martin R, Bergman C, Dalal M, Ruddle NH, McFarland HF (1993) T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes. Autoimmunity 15:137–143
    Waiczies S, Prozorovski T, Infante-Duarte C, Hahner A, Aktas O, Ullrich O, Zipp F (2005) Atorvastatin induces T cell anergy via phosphorylation of ERK1. J Immunol 174:5630–5635
    Weber MS, Youssef S, Dunn SE, Prod’Homme T, Neuhaus O, Stuve O, Greenwood J, Steinman L, Zamvil SS (2006) Statins in the treatment of central nervous system autoimmune disease. J Neuroimmunol 178:140–148
    Wen SR, Liu GJ, Feng RN, Gong FC, Zhong H, Duan SR, Bi S (2012) Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 244:94–96
    Willenborg DO, Fordham S, Bernard CC, Cowden WB, Ramshaw IA (1996) IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 157:3223–3227
    Yilmaz A, Reiss C, Tantawi O, Weng A, Stumpf C, Raaz D, Ludwig J, Berger T, Steinkasserer A, Daniel WG, Garlichs CD (2004) HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 172:85–93
    Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78–84
    Yu X, Pan Y, Ma H, Li W (2013) Simvastatin inhibits proliferation and induces apoptosis in human lung cancer cells. Oncol Res 20:351–357
    Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S (2008) Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol 180:6988–6996
    Zhang S, Rahman M, Qi Z, Herwald H, Thorlacius H (2011) Simvastatin regulates CXC chemokine formation in streptococcal M1 protein-induced neutrophil infiltration in the lung. Am J Physiol Lung Cell Mol Physiol 300:L930–L939